Vonoprazan for Acid-Related Diseases

Introduction to Vonoprazan Use

• The American Gastroenterological Association recommends that vonoprazan should generally not be used as first-line therapy for GERD or peptic ulcer disease but may be considered in patients who fail twice-daily PPI therapy 1, 2

Clinical Efficacy by Condition

• For peptic ulcer disease, vonoprazan 20 mg is comparable to lansoprazole 30 mg for gastric ulcer healing (94% vs 94% at 8 weeks) and duodenal ulcers (96% vs 98% at 6 weeks), as recommended by the American Gastroenterological Association 2
• For ulcer prophylaxis in patients on low-dose aspirin or NSAIDs with history of PUD, vonoprazan 10-20 mg is non-inferior to lansoprazole 15 mg, according to the American Gastroenterological Association 2
• Vonoprazan may be particularly effective for H. pylori-associated ulcers compared to idiopathic or NSAID-related ulcers, as noted by the American Gastroenterological Association 2

Clinical Considerations and Limitations

• The American Gastroenterological Association notes that cost considerations are important, as vonoprazan is significantly more expensive than standard and double-dose PPIs in the United States, which may limit its use as first-line therapy 1
• The American Gastroenterological Association also notes that while short-term safety appears comparable to PPIs, long-term safety data are more limited 1

Algorithm for Vonoprazan Use

• For GERD patients, the American Gastroenterological Association recommends starting with standard PPI therapy, escalating to twice-daily PPI if inadequate response, and considering vonoprazan 20 mg daily only after failure of twice-daily PPI therapy 1
• For Peptic Ulcer Disease, the American Gastroenterological Association recommends beginning with standard PPI therapy and reserving vonoprazan 20 mg daily for PPI treatment failures 2
• The American Gastroenterological Association also recommends considering vonoprazan for high-risk ulcer bleeding cases due to rapid and potent acid inhibition 2

Common Pitfalls to Avoid

• The American Gastroenterological Association advises against prescribing vonoprazan as first-line therapy for mild GERD or PUD when PPIs would be more cost-effective 1, 2
• The American Gastroenterological Association also advises against failing to consider the higher cost of vonoprazan compared to PPIs when making treatment decisions 1

Effectiveness of Vonoprazan in Maintaining GERD Compared to Other PPIs

Mechanism and Pharmacodynamics

• No cited facts are available for this section.

Effectiveness in Different GERD Subtypes

Non-Erosive Reflux Disease (NERD)

• The American Gastroenterological Association (AGA) does not recommend vonoprazan as first-line therapy for NERD 3
• Clinical trials show inconsistent results for vonoprazan in NERD, with one study finding minimal difference between vonoprazan and placebo, while another showed a trend toward improvement 4, 5

Mild Erosive Esophagitis (LA Grade A/B)

• Vonoprazan has similar healing efficacy to PPIs for LA grade A/B erosive esophagitis, with healing rates of 94% vs 91% for lansoprazole 4, 5
• Maintenance of healing rates at 24 weeks for LA grade A/B EE are slightly better with vonoprazan compared to lansoprazole, with rates of 81-82% vs 77% 5, 6

Severe Erosive Esophagitis (LA Grade C/D)

• Vonoprazan shows superior efficacy for maintenance of healing in severe EE (LA grade C/D) compared to lansoprazole, with healing rates of 75-77% vs 62% 6, 7
• A Japanese randomized trial showed significantly lower recurrence rates with vonoprazan 10-20 mg than lansoprazole 15 mg in LA grade C/D EE, with recurrence rates of 5-13% vs 39% 6, 7

Clinical Considerations and Limitations

• The AGA recommends against using vonoprazan as first-line therapy for acid-related conditions where clinical superiority has not been clearly demonstrated 8
• Cost considerations are significant, as vonoprazan is markedly more expensive than both standard and double-dose PPIs in the United States 4, 8
• Long-term safety data for vonoprazan are more limited than for PPIs, though short-term safety appears comparable with similar adverse event profiles 8

Vonoprazan Therapy in Specific Clinical Scenarios

H. pylori Eradication and Pharmacologic Superiority

• Vonoprazan provides 10-20% higher eradication rates when used in clarithromycin-based triple therapy, with superiority confined to clarithromycin-resistant strains, as supported by the American Gastroenterological Association 9, 10
• Dual therapy with vonoprazan and amoxicillin achieves eradication rates approaching 95% for first-line and 90% for second-line treatment, potentially eliminating the need for clarithromycin, according to the American Gastroenterological Association 9, 10
• Vonoprazan is not affected by CYP2C19 polymorphisms, resulting in more consistent acid suppression across different patient populations, as recommended by the American Gastroenterological Association 9, 10
• The use of vonoprazan can be supported by pH monitoring showing inadequate acid suppression, as part of the diagnostic workup for PPI failure 9

Vonoprazan Dosing for Acid-Related Diseases

Standard Dosing by Indication

• The American Gastroenterological Association recommends vonoprazan 20 mg once daily for 8 weeks for erosive esophagitis healing, achieving healing rates of approximately 94% 11
• The American Gastroenterological Association suggests vonoprazan 10 mg once daily for long-term maintenance of non-erosive reflux disease, though clinical trial data show inconsistent results 11

Clinical Positioning Algorithm

• The American College of Gastroenterology recommends against using vonoprazan as first-line therapy for mild erosive esophagitis, non-erosive reflux disease, or peptic ulcer disease where PPIs are equally effective but significantly less expensive 11
• The American College of Gastroenterology recommends vonoprazan 20 mg once daily for healing and 10 mg once daily for maintenance in patients with severe erosive esophagitis who fail twice-daily PPI therapy 11

Chronic Use of Vonoprazan in Recurrent Gastroesophageal Reflux Disease

Efficacy and Safety Considerations

• The American Gastroenterological Association does not recommend vonoprazan as first-line treatment for non-erosive reflux disease, with studies showing inconsistent results and minimal difference between vonoprazan and placebo 12
• Vonoprazan demonstrates robust efficacy in patients with gastroesophageal reflux disease resistant to proton pump inhibitors, with an improvement rate of 88% and a resolution rate of 42% 12
• The risk of enteric infections may be increased with chronic use of vonoprazan, similar to proton pump inhibitors, with a relative risk of 1.89 for community-acquired pneumonia 12

Predictors of Sustained Response

• Presence of erosive esophagitis before initiating vonoprazan is a positive predictor of sustained response, with a significantly higher resolution rate of 83% compared to 28% in patients without erosions 12

Investigation and Diagnosis

• Objective investigation, such as 24-hour pH monitoring, endoscopy, or esophagography, is necessary when empirical intensive therapy fails to control symptoms, as gastroesophageal reflux disease may not have been adequately controlled 12

Guideline Recommendations for Transitioning from Pantoprazole to Vonoprazan

Management of Patients Stable on Pantoprazole

• The American Gastroenterological Association recommends continuing pantoprazole at the lowest effective dose for long‑term gastro‑esophageal reflux disease (GERD) management when patients are stable on therapy. 13

Escalation Strategy After Pantoprazole Failure

• For patients who do not achieve symptom control with standard‑dose pantoprazole, the guideline advises escalating to pantoprazole 40 mg twice daily for a duration of 4–8 weeks before considering alternative agents. 13

Objective Testing Prior to Switching to Vonoprazan

• If symptoms persist despite twice‑daily pantoprazole, the AGA recommends performing objective diagnostic testing—including endoscopy and off‑medication pH monitoring—to confirm GERD and assess disease severity. This recommendation is supported by evidence from both Clinical Gastroenterology and Hepatology (2022) and Gut (2019). 13, 14